WO2019132625A1 - Composition pour prévenir, améliorer ou traiter la dermatite atopique, contenant un extrait d'herbes mixte en tant que principe actif - Google Patents

Composition pour prévenir, améliorer ou traiter la dermatite atopique, contenant un extrait d'herbes mixte en tant que principe actif Download PDF

Info

Publication number
WO2019132625A1
WO2019132625A1 PCT/KR2018/016941 KR2018016941W WO2019132625A1 WO 2019132625 A1 WO2019132625 A1 WO 2019132625A1 KR 2018016941 W KR2018016941 W KR 2018016941W WO 2019132625 A1 WO2019132625 A1 WO 2019132625A1
Authority
WO
WIPO (PCT)
Prior art keywords
atopic dermatitis
preventing
composition
active ingredient
extract
Prior art date
Application number
PCT/KR2018/016941
Other languages
English (en)
Korean (ko)
Inventor
이영호
강수영
Original Assignee
엔앤씨 메디메틱 주식회사농업회사법인
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔앤씨 메디메틱 주식회사농업회사법인 filed Critical 엔앤씨 메디메틱 주식회사농업회사법인
Publication of WO2019132625A1 publication Critical patent/WO2019132625A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a composition for preventing, improving or treating atopic dermatitis containing an herbal mixed extract as an active ingredient.
  • Atopic dermatitis is a disorder of the stratum corneum that acts as a protective barrier from the outermost part of the skin due to genetic, environmental, and immunological causes. It is a severe allergic disease in dry climates. Atopic dermatitis has a worldwide prevalence rate of 10 ⁇ 20%. It usually occurs in infants between 1 month and 1 year old. When they are 3 years old, it is alleviated to some extent.
  • Atopic dermatitis The main symptoms of atopic dermatitis are severe itching, skin dryness, rash, dirt, scabs and scaly skin (rabbits).
  • the itching that causes feelings of scratching is induced by itch mediators such as histamine.
  • the symptoms are easily alleviated by scratching.
  • scratching is more likely to cause scratching, Scratches.
  • Atopic dermatitis can be temporarily alleviated, but it can be recurred by stimuli such as the environment and food, and deterioration and mitigation are repeated.
  • the cause of atopic dermatitis is not well known, but it has been found to be related to the immune response, mainly due to a large number of genetic factors.
  • dry skin characteristic of easily itching of the skin compared with normal people, infection by bacteria, viruses, Emotional factors and environmental factors are known to occur due to their complex functions.
  • the inflammation associated with atopic dermatitis may be due to excessive immune cell action resulting in inflammatory cytokines such as TNF- ⁇ , tumor necrosis factor- ⁇ and interleukin-1 (IL-1, interleukin-1) (ROS), such as radicals (OH), superoxide radicals (O 2 -), hydrogen peroxide (H 2 O 2 ) and the like.
  • inflammatory cytokines such as TNF- ⁇ , tumor necrosis factor- ⁇ and interleukin-1 (IL-1, interleukin-1) (ROS), such as radicals (OH), superoxide radicals (O 2 -), hydrogen peroxide (H 2 O 2 ) and the like.
  • mast cells are known as the key cells causing acute and chronic inflammatory diseases in most allergic diseases including atopic dermatitis.
  • mast cells When mast cells are activated, they release inflammatory cytokines such as TNF- ⁇ , IL-1 and IL-6, as well as pruritogens such as histamine.
  • inflammatory cytokines derived from mast cells further promote the inflammatory reaction, while promoting the secretion of itch-like substances such as histamine, thereby causing skin barrier disruption.
  • identifying substances that can inhibit inflammatory cytokines and itch-mediated substances without side effects will be effective in controlling allergic diseases, including atopic dermatitis.
  • the prescription for atopic dermatitis is mainly drug therapy such as steroids, antihistamines, antibiotics and the like.
  • Steroids are largely anti-inflammatory and immunosuppressive and have excellent effects, but when applied for a long time, side effects such as skin weakness, systemic hormone symptoms, and addiction may occur.
  • the current treatment for atopic dermatitis is to use immunosuppressants and new antihistamines.
  • antihistamines alone can not completely block allergic reactions. This is because histamine is not the only chemical messenger that causes allergic reactions. Therefore, it is required to develop a composition for treating atopic dermatitis which is effective for atopic dermatitis but has no side effects.
  • Orostachys japonicus is a perennial herb of Crassulaceae, and its major origins are Korea, China, and Japan. Pharmacologically, it is known that vasoconstriction, excitement, intestinal enhancement of intestinal tract, , Diuretic and the like. It is mainly used as a treatment for cancer, especially in summer and autumn.
  • Eclipta prostrate is an annual plant of Compositae which is 10 ⁇ 70 cm high. It is a plant that grows in bean fields in Jeju, South and central part of Korea. It has been known to be effective in promoting blood flow, pain, immunity, dermatitis, promoting hair growth, and dermatitis, which is cracked in skin, and is known to be effective for alleviating skin irritation.
  • Zizania latifolia is a perennial plant of Poaceae that grows about 1 to 2 meters in height and grows in the mud with thick, short roots extending to the side.
  • Leaf length is about 50cm ⁇ 1m and width is about 2 ⁇ 3cm, lower part is round and tip is sharp.
  • the leaf of Julpoo contains 1.2% of protein, 0.1% of oil and 0.5% of ash, and both outpost and rootstock have phlegm, diuretic, balancing the stomach and stomach, Diarrhea, kidney disease, heart disease, liver disease, lung disease, kidney disease, gastrointestinal disease.
  • Portulaca oleracea is a one-year-old herb of Portulacaceae. It grows in May and September in a largely gardens and garden gardens. Its height is about 15 to 30 cm in height and has no hairs. Its stem is reddish It is a plant that grows as branches divide and spread diagonally to the ground. According to recent studies, it has been known that the extract of Maji is effective for anti-gastritis, bronchial asthma mitigation, wound healing, antimicrobial activity and antifungal activity.
  • Artemisia princeps is one of perennial plants belonging to Compositae. It can be cultivated in an environmentally friendly way without the use of pesticides. It can be used for antimicrobial activity, bronchodilating action, capillary action, blood coagulation inhibitory action, The effect is known. It has been developed into a variety of health foods or cosmetics using mugwort. It has been used in cosmetic perfumes, preservatives, antimicrobial cosmetics, sanitary napkins, moxibustion, fumigation bathing baths, and bath salts.
  • Eriobotrya japonica is an evergreen tree belonging to Rosaceae, which is used as a medicinal herb, root, stem skin and leaf.
  • the non-foliage is a medicine with a taste and a cold nature. It releases the heat of the lungs to stop the coughing and remove the sputum. It works on the vomiting and hiccups.
  • Sasa borealis is an evergreen shrub belonging to the genus Poaceae, and contains excellent functionality. Recently, attention has been focused on its efficacy as it is known to many people.
  • the efficacy of sanjuk revealed in modern medicine is mainly anticancer, sterilization and anti-ulcer action, and also brings heat to the disposal, and is effective in anti-inflammation, sedation, analgesic action, enhancement of gastric acidity, prevention of arteriosclerosis, And tonic action.
  • Folk remedies are also used for bleeding, eye disease, burns, swelling and athlete's foot due to various causes.
  • Dendropanax morbifera is an evergreen broad-leaved tree belonging to the Araliaceae. It is an evergreen broad-leaved tree belonging to Araliaceae. It is locally distributed in Korea, especially in the southern coasts of South Korea and temperate regions such as Jeju Island, Wando, Haenam, It is a special species. If you bruise the bark of Huchilchu tree, a small amount of yellow sap is produced. It is called Huchil. The efficacy of Hwangchil is known to improve blood circulation, improve liver function, antioxidant effect, immunity enhancement, nervous stability, antimicrobial activity and anticancer activity.
  • Korean Patent No. 1544176 discloses a cosmetic composition comprising a method of stabilizing skin whitening, wrinkle, anti-inflammation and antioxidative activity and a stabilized Jeju borax extract of Jeju whitewash tree extract, and Korean Patent No. 0946583 Discloses a cosmetic composition for skin moisturizing which contains an extract of Wassong as an active ingredient but does not disclose a composition for preventing, improving or treating atopic dermatitis containing the herbal mixed extract of the present invention as an active ingredient.
  • the present invention has been made in view of the above needs, and the inventors of the present invention have found that a mixed extract of 8 kinds of herbs (watson, hanxi, japon, mashihi, mugwort, Thymus and activation regulated chemokine), IL-8 (Interleukin-8) and ICAM-1 (Intercellular Adhesion Molecule 1).
  • the present invention provides a cosmetic composition for prevention or improvement of atopic dermatitis containing an herbal mixed extract as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating atopic dermatitis containing an herbal composition-mixed extract as an active ingredient.
  • the present invention also provides a health functional food composition for preventing or ameliorating atopic dermatitis containing an herbal mixed extract as an active ingredient.
  • the herbal mixed extract of the present invention is excellent in the effect of reducing the expression of TARC, IL-8 and ICAM-1, which are atopic skin inflammation markers, without cytotoxicity. Therefore, Cosmetics or atopic dermatitis.
  • FIG. 1 shows the result of analysis of cytotoxicity after treatment of HaCaT cells (human keratinocyte cell line) with hot-water extract (A) or ethanol extract (B) of herbal mixture.
  • Fig. 2 shows the results of the ethanol extract (EE; 0.5 ⁇ g / ml, 1 ⁇ g / ml) of the hydrothermal extract of the herbal mixture (WE: 0.5 ⁇ g / ml, 1 ⁇ g / ml) or the herbal mixture in HaCaT cells treated with TNF- (IL-8) and ICAM-1 (Intercellular Adhesion Molecule 1; C) according to the treatment of TARC / TI; TNF- ⁇ and IFN- ⁇ to treat atopic dermatitis. control; Untreated control without TNF-a and IFN-y treatment.
  • EE 0.5 ⁇ g / ml, 1 ⁇ g / ml
  • WE 0.5 ⁇ g / ml, 1 ⁇ g / ml
  • ICAM-1 Intercellular Adhesion Molecule 1; C
  • the present invention provides a cosmetic composition for prevention or improvement of atopic dermatitis containing an herbal mixed extract as an active ingredient.
  • the herbal mixed extract may be extracted using water, a lower alcohol having 1 to 4 carbon atoms, a mixture of water and a lower alcohol, or a vegetable oil as an extraction solvent, but is not limited thereto.
  • the vegetable oil is not limited thereto, but may be uniquely exemplified by jojoba oil, evening primrose oil, sweet almond, camellia oil, tamanu oil or avocado.
  • Extracts when water is used in the extraction solvent, purified water of 10 to 50 times the weight of the mixture is added to the herbal mixture of eight herbs, extracted with a vacuum extractor at 85 to 105 ° C, Extracts can be prepared.
  • composition according to an embodiment of the present invention when lower alcohol is used in the extraction solvent, 60 to 100% ethanol of 10 to 50 times the weight of the mixture is added to 8 kinds of herbal mixture, To produce an ethanol extract of the herbal mixture.
  • 70% ethanol can be preferably used as a solvent.
  • the herbal mixture when the vegetable oil is used in the extraction solvent, the herbal mixture is added with 10 to 50 times of the vegetable oil to the weight of the mixture, and extracted with a vacuum extractor at 20 to 80 ° C An oil extract of the herbal mixture can be prepared.
  • the cosmetic composition for improving atopic dermatitis may be in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing oil, powder foundation, A cream, a softener, a nutrient lotion, a pack, an essence, a hair tonic, a shampoo, a rinse, a hair conditioner, a hair conditioner, a hair conditioner, Lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutritional cream, eye cream, moisturizing cream, hand cream, foundation, nutrition essence, sunscreen, skin lotion, skin toner, , Soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions and body cleansers You can have a single dosage form slow, but not limited to this.
  • the composition of each of these formulations may contain various kinds of bases and additives necessary for formulation of the formulation, and the kinds and amounts of these ingredients can be easily selected by those skilled in the art.
  • the formulation of the present invention is a paste, cream or gel, animal fibers, plant fibers, wax, paraffin, starch, tracant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier components .
  • the formulation of the present invention is a powder or a spray
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component.
  • a spray in particular, / Propane or dimethyl ether.
  • a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
  • the formulation of the present invention is a suspension
  • a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc.
  • a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc.
  • the carrier component is selected from aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolenic derivatives or ethoxylated glycerol fatty acid esters.
  • the present invention also provides a pharmaceutical composition for preventing or treating atopic dermatitis containing an herbal mixed extract as an active ingredient.
  • the herbal mixed extract may contain 0.5 to 3: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5, and then the mixture is extracted.
  • the herbal mixed extract may be water, a lower alcohol having 1 to 4 carbon atoms, a mixture of water and a lower alcohol, or a vegetable oil as an extraction solvent, but is not limited thereto.
  • the herbal mixed extract inhibits the expression of TARC (Thymus and activation regulated chemokine), IL-8 (Interleukin-8) and ICAM-1 (Intercellular Adhesion Molecule 1) .
  • the pharmaceutical composition for preventing or treating atopic dermatitis of the present invention may further comprise a suitable carrier, excipient or diluent conventionally used in the production of a pharmaceutical composition.
  • a suitable carrier, excipient or diluent conventionally used in the production of a pharmaceutical composition.
  • the pharmaceutical dosage forms of the compositions according to the invention may be used alone or in combination with other pharmaceutically active compounds as well as in suitable combinations.
  • the pharmaceutical composition according to the present invention may be formulated in the form of powders, granules, tablets, capsules, oral preparations such as suspensions, emulsions, syrups and aerosols, external preparations, suppositories and injections according to conventional methods .
  • Examples of carriers, excipients and diluents that can be included in the pharmaceutical composition including the herbal mixed extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium A variety of compounds or mixtures including phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, .
  • a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used.
  • Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, .
  • lubricants such as magnesium stearate and talc are also used.
  • liquid formulations for oral use include suspensions, solutions, emulsions and syrups.
  • Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
  • the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like.
  • the suppository base include withexol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
  • the preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art.
  • the pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.
  • the present invention also provides a health functional food composition for preventing or ameliorating atopic dermatitis containing an herbal mixed extract as an active ingredient.
  • the herbal mixed extract may contain 0.5 to 3: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 0.5: But the present invention is not limited thereto, and they may be extracted after mixing at a weight ratio of 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5.
  • the herbal mixed extract may be water, a lower alcohol having 1 to 4 carbon atoms, a mixture of water and a lower alcohol, or a vegetable oil as an extraction solvent, but is not limited thereto.
  • the health functional food composition for preventing or ameliorating atopic dermatitis of the present invention may be manufactured by any one of formulations selected from granules, rings, tablets, capsules, candies, syrups and beverages, but is not limited thereto.
  • the health functional food composition is not particularly limited as long as it can be ingested to prevent or ameliorate atopic dermatitis.
  • the health functional food composition of the present invention When used as a food additive, the health functional food composition may be added as it is, or may be used together with other food or food ingredients, and suitably used according to a conventional method.
  • the active ingredient may be suitably used depending on its intended use (prevention or improvement). However, in the case of long-term intake for the purpose of controlling health, it can be used in an amount that does not cause any safety problems. There is no particular limitation on the kind of the food.
  • Examples of the foods to which the health functional food composition can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, soups, Drinks, alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.
  • the health functional food composition of the present invention can be produced as a food, particularly a functional food.
  • the functional food of the present invention includes components that are ordinarily added in food production, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings.
  • a natural carbohydrate or a flavoring agent may be included as an additional ingredient in addition to the active ingredient.
  • the natural carbohydrate may be selected from the group consisting of monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose etc.), oligosaccharides, polysaccharides (e.g., dextrin, cyclodextrin, , Xylitol, sorbitol, erythritol, etc.).
  • the flavoring agent may be a natural flavoring agent (e.g., tau Martin, stevia extract, etc.) and a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).
  • the hydrothermal extracts of the herbal mixture were 0.5, 0.5, 2, 3, 4, 5, 6,
  • the mixture is mixed in a weight ratio of 3: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5, and 10 to 50 times of purified water is added to the mixture Extracted from a vacuum extractor at 80 to 105 ° C, and lyophilized at -120 ° C or lower.
  • the ethanol extracts of the herbal mixture are selected from the group consisting of 0.5 to 3: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5 : 0.5 to 1.5.
  • the mixture was added with 10 to 50 times by weight of 60 to 100% ethanol, and the mixture was extracted with a vacuum extractor at 80 to 105 ° C. and lyophilized at -120 ° C. or less.
  • the oil extracts of the herbal mixture are selected from the group consisting of 0.5 to 3: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5 : 0.5 to 1.5, and then 10 to 50 times by weight of vegetable oil (such as jojoba, evening primrose oil, sweet almond, camellia oil, tamarin or avocado oil) is added to the mixture, And extracted.
  • vegetable oil such as jojoba, evening primrose oil, sweet almond, camellia oil, tamarin or avocado oil
  • HaCaT cells human keratinocyte cell line, were cultured in RPMI medium containing 10% FSB (fetal bovine serum) and antibiotics (penicillin) and cultured at 37 ° C in a 5% CO 2 incubator.
  • the cultured HaCaT cells were dispensed into a 24-well plate, and the hot-water extract and the ethanol extract of the herbal mixture were treated with 0.5, 1, 5, 10 and 100 ⁇ g / And reacted for 4 hours.
  • Absorbance was measured at 570 nm using an absorbance meter.
  • HaCaT cells were cultured in RPMI medium supplemented with 10% FSB and antibiotics, cultured in a 5% CO 2 incubator at 37 ° C for 24 hours, replaced with serum-free medium, and cultured for 16 hours. (0.5 and 1 / / ml) were treated with TNF- ⁇ and IFN- ⁇ for 4 hours, and then trizol was added to the cells, followed by homogenization Respectively. After the homogenized cells were centrifuged with chloroform, the supernatant was obtained. Isopropanol was added to the supernatant, centrifuged to extract only RNA, and the extracted RNA was subjected to RT-PCR (reverse transcriptional polymerase chain reaction).
  • RT-PCR reverse transcriptional polymerase chain reaction
  • TARC thymus and activation-regulated chemokine
  • IL-8 interleukin-8
  • ICAM-1 intercellular adhesion molecule 1
  • GAPDH Glyceraldehyde 3-phosphate dehydrogenase
  • MTT assays were performed to analyze the cytotoxicity of the herbal mixed extract of the present invention.
  • the hydrothermal extract and the ethanol extract of the herbal mixture of the present invention had no effect on the cell viability at concentrations of 1 ⁇ g / ml and 5 ⁇ g / ml, respectively.
  • the hot water extract was 1 ⁇ g / Was not cytotoxic to 5 [mu] g / ml (Fig. 1).
  • TARC, IL-8 and ICAM-1 were significantly increased in the group (Tl) in which atopic dermatitis was treated by treating TNF- ⁇ and IFN- ⁇ , IL-8 and ICAM-1 were significantly higher in the group treated with hot water extract (WE 0.5, WE 1) and ethanol extract (EE 0.5, EE 1, respectively) 1 gene was significantly reduced (FIG. 2).

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition pour prévenir, améliorer ou traiter la dermatite atopique, contenant des extraits d'herbes mixtes en tant que principe actif. Les extraits d'herbes mixtes de la présente invention ont pour effet d'inhiber significativement l'expression de TARC, d'IL-8 et d'ICAM-1 en tant que facteurs inflammatoires qui provoquent la dermatite atopique. Par conséquent, la composition de la présente invention peut être utilisée efficacement pour le développement d'un agent thérapeutique pour la dermatite atopique ou pour le développement d'un aliment santé fonctionnel ou d'un produit cosmétique fonctionnel pour des patients atteints de dermatite atopique.
PCT/KR2018/016941 2017-12-28 2018-12-28 Composition pour prévenir, améliorer ou traiter la dermatite atopique, contenant un extrait d'herbes mixte en tant que principe actif WO2019132625A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170181983 2017-12-28
KR10-2017-0181983 2017-12-28

Publications (1)

Publication Number Publication Date
WO2019132625A1 true WO2019132625A1 (fr) 2019-07-04

Family

ID=67067959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/016941 WO2019132625A1 (fr) 2017-12-28 2018-12-28 Composition pour prévenir, améliorer ou traiter la dermatite atopique, contenant un extrait d'herbes mixte en tant que principe actif

Country Status (2)

Country Link
KR (1) KR20190080821A (fr)
WO (1) WO2019132625A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113416122A (zh) * 2021-06-09 2021-09-21 辽宁中医药大学 马齿苋中一种芳基类化合物的提取分离方法及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102088329B1 (ko) * 2019-10-25 2020-03-12 장은정 자주방아풀 추출물을 유효성분으로 함유하는 소양증의 예방 또는 치료용 약학적 조성물
KR102408518B1 (ko) * 2021-10-28 2022-06-13 주식회사 세바바이오텍 아토피 피부염 예방 또는 개선용 조성물
JP7315278B1 (ja) * 2023-03-15 2023-07-26 マスダ商事株式会社 皮膚疾患改善剤の製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110045140A (ko) * 2009-10-26 2011-05-04 지영학 부들, 조릿대, 갈대 및 줄풀을 포함하는 한방음료
KR20130030491A (ko) * 2011-09-19 2013-03-27 최양원 아토피 및 여드름 치료용 생약조성물
KR101302222B1 (ko) * 2012-09-18 2013-08-30 주식회사 아가방앤컴퍼니 아토피 피부염 및 알레르기성 피부질환 예방, 개선 및 치료용 식물성 혼합 추출물, 이를 포함하는 조성물 및 이의 제조방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110045140A (ko) * 2009-10-26 2011-05-04 지영학 부들, 조릿대, 갈대 및 줄풀을 포함하는 한방음료
KR20130030491A (ko) * 2011-09-19 2013-03-27 최양원 아토피 및 여드름 치료용 생약조성물
KR101302222B1 (ko) * 2012-09-18 2013-08-30 주식회사 아가방앤컴퍼니 아토피 피부염 및 알레르기성 피부질환 예방, 개선 및 치료용 식물성 혼합 추출물, 이를 포함하는 조성물 및 이의 제조방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Looking for promising bio-aging companies in Gyeongnam (3) Sancheong N & C Medical Co., Ltd.", GYEONGNAM NEWSPAPER, ECONOMY, 27 February 2017 (2017-02-27), pages 1 - 2, Retrieved from the Internet <URL:http://www.knnews.co.kr/news/articleView.php?idxno=1207149> *
CEO YOUNG-HO LEE: "Natural Cheongmyeong Herbal Cosmetics '' made with Jirisan Herbs", NATURALTIMES.KR, 21 September 2017 (2017-09-21), pages 1 - 4, Retrieved from the Internet <URL:http://www.naturaltimes.kr/news/newsview.php?ncode=1065542480340578&dt=m> *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113416122A (zh) * 2021-06-09 2021-09-21 辽宁中医药大学 马齿苋中一种芳基类化合物的提取分离方法及其应用

Also Published As

Publication number Publication date
KR20190080821A (ko) 2019-07-08

Similar Documents

Publication Publication Date Title
WO2019132625A1 (fr) Composition pour prévenir, améliorer ou traiter la dermatite atopique, contenant un extrait d&#39;herbes mixte en tant que principe actif
KR100772575B1 (ko) 생약성분 추출물을 함유하는 피부 외용제 조성물
KR102348042B1 (ko) 산수국 추출물을 포함하는 피부 상태 개선용 조성물
KR101874462B1 (ko) 오미자 잎 추출물을 유효성분으로 포함하는 아토피 피부염의 예방, 개선 또는 치료용 조성물
JP2003192605A (ja) リパーゼ阻害剤
KR101367423B1 (ko) 피부 개선용 약학 조성물, 화장료 조성물 및 그 제조방법
KR20150086982A (ko) 원지 추출물을 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 조성물
KR101934794B1 (ko) 고욤잎 및 포도송이 가지의 혼합 추출물을 유효성분으로 함유하는 아토피 피부염의 예방, 개선 또는 치료용 조성물
KR100999870B1 (ko) 어성초 및 느릅나무 혼합추출물을 유효 성분으로 함유하는알레르기성 피부질환 예방 및 치료용 약학적 조성물
KR101330411B1 (ko) 증숙 처리된 녹차 추출물을 유효성분으로 함유하는 아토피 피부염 개선용 조성물
KR102197858B1 (ko) 혼합 생약 추출물을 유효성분으로 포함하는 건선 예방 또는 치료용 약학적 조성물
KR20130016930A (ko) 세이지 추출물, 레몬밤 추출물, 우뭇가사리 추출물 및 양파 추출물을 유효성분으로 포함하는 아토피 피부 및 피부 자극 완화용 화장료 조성물
KR20160128589A (ko) 천연 추출물을 포함하는 염증성 피부질환 개선용 조성물
KR102142461B1 (ko) 구상나무 추출물을 포함하는 피부 상태 개선용 조성물
KR101891218B1 (ko) 천연 추출물을 포함하는 피부염 질환의 치료용 조성물
KR102114133B1 (ko) 알피나 골무꽃 추출물을 포함하는 탈모 방지 또는 육모 촉진용 조성물
KR101842786B1 (ko) 생약 혼합 추출물을 포함하는 아토피 피부염의 치료용 조성물
KR101698869B1 (ko) 한약재를 유효성분으로 함유하는 아토피 피부염 예방 또는 치료용 조성물
KR20120077889A (ko) 송엽 또는 송절의 추출물을 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 조성물
KR20090107342A (ko) 어성초, 금전초, 차전초, 느릅나무 및 상엽 혼합추출물을유효 성분으로 함유하는 알레르기성 피부질환 예방 및치료용 약학적 조성물
KR20090075950A (ko) 난치성 아토피성 피부염 치료용 조성물
KR102144566B1 (ko) 택란 추출물을 유효성분으로 포함하는 아토피 피부염의 예방 또는 치료용 조성물
KR20120057160A (ko) 자라 추출물을 함유하는 피부질환의 개선 또는 치료용 약학적 조성물
KR100900197B1 (ko) 특정 식물추출 혼합물을 함유하는 피부면역억제용 피부 외용제 조성물
KR101658429B1 (ko) 감피 초임계 추출물을 유효성분으로 함유하는 아토피 피부염 예방 또는 개선용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18896433

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18896433

Country of ref document: EP

Kind code of ref document: A1